# Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

> **NCT05601167** · PHASE3 · COMPLETED · sponsor: **Promomed, LLC** · enrollment: 264 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** nirmatrelvir/ritonavir
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05601167
- **Lead sponsor:** Promomed, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2023-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601167, "Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05601167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*